vs
Side-by-side financial comparison of BTCS Inc. (BTCS) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.
Sunshine Biopharma Inc. is the larger business by last-quarter revenue ($8.6M vs $7.1M, roughly 1.2× BTCS Inc.). On growth, BTCS Inc. posted the faster year-over-year revenue change (205.5% vs -10.6%). Sunshine Biopharma Inc. produced more free cash flow last quarter ($-1.6M vs $-9.8M). Over the past eight quarters, BTCS Inc.'s revenue compounded faster (296.4% CAGR vs 6.6%).
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
BTCS vs SBFM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.1M | $8.6M |
| Net Profit | — | $-2.1M |
| Gross Margin | 12.4% | 35.3% |
| Operating Margin | — | -20.9% |
| Net Margin | — | -25.0% |
| Revenue YoY | 205.5% | -10.6% |
| Net Profit YoY | — | 0.8% |
| EPS (diluted) | $-1.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.1M | $8.6M | ||
| Q3 25 | $4.9M | $9.4M | ||
| Q2 25 | $2.8M | $9.4M | ||
| Q1 25 | $1.7M | $8.9M | ||
| Q4 24 | $2.3M | $9.6M | ||
| Q3 24 | $739.2K | $8.4M | ||
| Q2 24 | $561.2K | $9.3M | ||
| Q1 24 | $451.4K | $7.5M |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $65.6M | $-883.8K | ||
| Q2 25 | $3.9M | $-1.8M | ||
| Q1 25 | $-17.3M | $-1.2M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-9.0M | $-1.2M | ||
| Q2 24 | $-6.7M | $-494.3K | ||
| Q1 24 | $12.3M | $-1.3M |
| Q4 25 | 12.4% | 35.3% | ||
| Q3 25 | 22.0% | 32.6% | ||
| Q2 25 | -2.9% | 36.4% | ||
| Q1 25 | 7.1% | 30.7% | ||
| Q4 24 | 2.9% | 32.2% | ||
| Q3 24 | 26.5% | 34.0% | ||
| Q2 24 | 69.9% | 25.3% | ||
| Q1 24 | 64.4% | 31.2% |
| Q4 25 | — | -20.9% | ||
| Q3 25 | — | -11.5% | ||
| Q2 25 | — | -21.8% | ||
| Q1 25 | — | -14.6% | ||
| Q4 24 | — | -21.7% | ||
| Q3 24 | — | -13.1% | ||
| Q2 24 | — | -13.6% | ||
| Q1 24 | — | -17.9% |
| Q4 25 | — | -25.0% | ||
| Q3 25 | 1328.1% | -9.4% | ||
| Q2 25 | 140.0% | -18.8% | ||
| Q1 25 | -1022.5% | -13.3% | ||
| Q4 24 | — | -22.5% | ||
| Q3 24 | -1223.0% | -14.2% | ||
| Q2 24 | -1198.9% | -5.3% | ||
| Q1 24 | 2715.3% | -17.0% |
| Q4 25 | $-1.58 | — | ||
| Q3 25 | $1.30 | $-0.54 | ||
| Q2 25 | $0.14 | $-0.82 | ||
| Q1 25 | $-0.86 | $-0.44 | ||
| Q4 24 | $0.28 | $49.77 | ||
| Q3 24 | $-0.56 | $-11.61 | ||
| Q2 24 | $-0.43 | $-43.48 | ||
| Q1 24 | $0.63 | $-2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.4M | $23.0M |
| Total Assets | $214.6M | $30.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5M | — | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $639.2K | — | ||
| Q1 25 | $269.9K | — | ||
| Q4 24 | $2.0M | — | ||
| Q3 24 | $254.5K | — | ||
| Q2 24 | $536.7K | — | ||
| Q1 24 | $670.6K | — |
| Q4 25 | $139.4M | $23.0M | ||
| Q3 25 | $225.4M | $24.2M | ||
| Q2 25 | $31.1M | $25.7M | ||
| Q1 25 | $20.6M | $22.7M | ||
| Q4 24 | $34.0M | $23.5M | ||
| Q3 24 | $25.2M | $25.0M | ||
| Q2 24 | $33.1M | $23.5M | ||
| Q1 24 | $39.3M | $24.8M |
| Q4 25 | $214.6M | $30.1M | ||
| Q3 25 | $298.9M | $31.5M | ||
| Q2 25 | $40.8M | $32.0M | ||
| Q1 25 | $21.0M | $29.2M | ||
| Q4 24 | $38.2M | $30.6M | ||
| Q3 24 | $26.5M | $30.1M | ||
| Q2 24 | $33.8M | $29.3M | ||
| Q1 24 | $39.5M | $31.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.8M | $-1.6M |
| Free Cash FlowOCF − Capex | $-9.8M | $-1.6M |
| FCF MarginFCF / Revenue | -138.1% | -18.9% |
| Capex IntensityCapex / Revenue | 0.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-15.8M | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.8M | $-1.6M | ||
| Q3 25 | $-2.8M | $-727.8K | ||
| Q2 25 | $-1.3M | $-1.3M | ||
| Q1 25 | $-1.9M | $-1.7M | ||
| Q4 24 | $-3.5M | $-3.4M | ||
| Q3 24 | $-695.2K | $-1.4M | ||
| Q2 24 | $-924.1K | $-4.6M | ||
| Q1 24 | $-769.0K | $-3.2M |
| Q4 25 | $-9.8M | $-1.6M | ||
| Q3 25 | $-2.8M | $-735.8K | ||
| Q2 25 | $-1.3M | $-1.4M | ||
| Q1 25 | $-1.9M | $-1.7M | ||
| Q4 24 | $-3.5M | $-3.5M | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | $-5.6M | ||
| Q1 24 | — | $-3.2M |
| Q4 25 | -138.1% | -18.9% | ||
| Q3 25 | -56.7% | -7.8% | ||
| Q2 25 | -48.2% | -15.2% | ||
| Q1 25 | -112.7% | -19.3% | ||
| Q4 24 | -152.2% | -36.6% | ||
| Q3 24 | — | -22.2% | ||
| Q2 24 | — | -59.7% | ||
| Q1 24 | — | -43.1% |
| Q4 25 | 0.2% | 0.0% | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | 0.1% | 1.7% | ||
| Q1 25 | 0.1% | 0.1% | ||
| Q4 24 | 0.1% | 1.1% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | — | 10.5% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.34× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BTCS
| Builder Plus | $5.9M | 83% |
| Other | $1.2M | 17% |
SBFM
Segment breakdown not available.
